Risk Assessment of Nanoformulations.

Risk Assessment of Nanoformulations. Recent Pat Drug Deliv Formul. 2015 Apr 7; Authors: Sharma HK Abstract In this era of Nanomedicine, Molecular medicine or Nanoformulations, I felt it to be worthy to raise certain issues for everyday discussion among the nanotechnologists, biologists, toxicologists and environmental scientists. The issues require involvement of all of them and relate the toxicity aspect of nanoformulations and assessment of risk-benefit ratio. The changes in surface properties due to reduction of particle size increase the possibility of alteration in binding affinities with biological macromolecules. The toxicity profile of nanoparticles is different from that of larger particles with similar chemical composition [1-2] and has also been reported to control the fate of interstitially injected nanoparticles [3]. The rapid increase in the use of nanoformulations/ nanomaterials, all flora and fauna will be affected as these can cross the cellular barriers, which may cause damage or alteration of cellular materials and may proved to be an unknown, uncontrolled potential ecotoxic substance. Exhaustive studies would help in highlighting such alterations; particularly, on the key targets and to the system as a whole. Besides the study of the changes due to changes in surface properties of drug, it is also equally, rather, more significantly important to study the toxicity of nanocarriers [1-2]. Several reports including p...
Source: Recent Patents on Drug Delivery and Formulation - Category: Drugs & Pharmacology Tags: Recent Pat Drug Deliv Formul Source Type: research